Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Company Deals

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company

Sino Biopharmaceutical Reports 10.7% Revenue Growth and 140.2% Profit Surge in H1 2025

Fineline Cube Aug 19, 2025

China-based Sino Biopharmaceutical Limited (HKG: 1177) announced its financial results for the first half of 2025....

Company Drug

Kangtai Biological Gains NMPA Approval for Trivalent Influenza Vaccine Clinical Trial

Fineline Cube Aug 19, 2025

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that it has received approval from...

Company Drug

Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval

Fineline Cube Aug 19, 2025

Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis,...

Company Digital

RemeGen Inks Licensing Deal With Santen China for RC28-E Eye Disease Drug

Fineline Cube Aug 19, 2025

China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an agreement with Santen China, a...

Company Medical Device

MicroPort CardioFlow’s Alwide Plus Wins EU CE Mark for Heart Valve Procedures

Fineline Cube Aug 19, 2025

China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), based in China, announced that its independently...

Company Drug

Mabwell’s Innovative CDH17-Targeted ADC 7MW4911 Receives FDA Clinical Trial Approval

Fineline Cube Aug 19, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its self-developed CDH17-targeted antibody-drug conjugate...

Company Drug

Hengrui Pharma’s Hetrombopag Olamine Accepted by NMPA for Chemotherapy-Induced Thrombocytopenia

Fineline Cube Aug 19, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the National Medical Products...

Company

WuXi XDC Reports Strong H1 2025 Growth With 62.2% Revenue Increase

Fineline Cube Aug 19, 2025

China-based WuXi XDC Cayman Inc. (HKG: 2268), a leading global Contract Research, Development, and Manufacturing...

Company Deals Drug

Genentech to End $2B Collaboration With Adaptive Biotechnologies on T-Cell Therapies

Fineline Cube Aug 19, 2025

Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), will terminate its strategic...

Company Deals

Henlius Partners with GeneQuantum on HER2-Targeted ADC GQ1005 Development

Fineline Cube Aug 19, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic collaboration with China-based GeneQuantum Healthcare. The...

Company Medical Device

Acotec Scientific’s Micro-Guidewire Receives Beijing Medical Products Administration Approval

Fineline Cube Aug 19, 2025

China-based Acotec Scientific Holdings Limited (HKG: 6669) announced that its micro-guidewire has received registration approval...

Company Deals

Skyhawk Therapeutics Collaborates with Merck on RNA-Targeting Small Molecules for Neurological Diseases

Fineline Cube Aug 19, 2025

Skyhawk Therapeutics, Inc. announced on August 18, 2025, a strategic research collaboration with Merck KGaA...

Company Drug

Sichuan Biokin’s Iza-Bren Granted FDA Breakthrough Therapy Designation for NSCLC

Fineline Cube Aug 19, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC), izalontamab...

Company Drug

Ascentage Pharma’s Lisaftoclax Gains FDA and EMA Clearance for Global Phase III Trial

Fineline Cube Aug 18, 2025

Ascentage Pharma Group International (HKG: 6855) announced that it has received clearance from the U.S....

Company Drug

Novo Nordisk’s Wegovy Granted FDA Approval for Metabolic-Associated Steatohepatitis

Fineline Cube Aug 18, 2025

Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced on August 15, 2025, that its...

Company Drug

Livzon Announces NMPA Acceptance of JP-1366 Tablets Application for Reflux Esophagitis

Fineline Cube Aug 18, 2025

Livzon Pharmaceutical Group Inc. (HKG: 1513) announced that the drug registration application for its JP-1366...

Company Drug

iRegene Therapeutics’ NouvNeu001 Receives FDA Fast Track Designation for Parkinson’s Therapy

Fineline Cube Aug 18, 2025

China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has...

Company Drug

Ab&B Bio-Tech’s RSV Vaccine Gains IND Approval in China and the U.S.

Fineline Cube Aug 18, 2025

China-based Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that its self-developed investigational new drug...

Company Drug

Haisco’s HSK39297 Gains NMPA Approval for AMD and gMG Trials

Fineline Cube Aug 18, 2025

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the National Medical Products Administration (NMPA)...

Company Drug

FDA Accelerates Approval of Dordaviprone for H3 K27M-Mutant Diffuse Midline Glioma

Fineline Cube Aug 18, 2025

The U.S. Food and Drug Administration (FDA) granted accelerated approval on August 6, 2025, to...

Posts pagination

1 … 136 137 138 … 688

Recent updates

  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
  • AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.